DOCSLIB.ORG

Imipramine 10Mg and 25Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

passing water (urine), dilation of the pupil of • The other ingredients are carnauba wax, the eye, glaucoma and blockage of the small colloidal silica, gelatin, lactose, magnesium intestine) stearate, maize starch, polyvidone, stearic Package leaflet: Information for the patient Heart: feeling faint when getting up (postural acid, sucrose, E170, E171, E211, E414, E460, hypotension), high or severely low blood and E553. The 10mg tablets also contain pressure, fast/racing heart, palpitations, E110, E123 and E127. The 25mg tablets also Imipramine 10mg irregular heartbeats, changes in ECG readings contain sodium hydroxide, E216 and E218 Stomach and intestines: feeling or being and E172. and 25mg tablets sick, loss of appetite, inflammation of the Read all of this leaflet carefully before • have heart disease such as irregular heart mucus membranes in the mouth, tongue What Imipramine tablets look like and you start taking this medicine because it beats, heart block or have recently had a lesions contents of the pack contains important information for you. heart attack Liver: impaired liver function, hepatitis, Imipramine tablets are red (10mg) or tan • Keep this leaflet. You may need to read it • suffer from periods of increased and including changes in liver function (as seen in (25mg) circular, biconvex, sugar-coated again. exaggerated behaviour (mania) blood tests), jaundice (yellowing of the skin tablets, diameter 5.9mm (10mg) or 6.4mm • If you have any further questions, ask • have severe liver disease and/or whites of the eyes) (25mg). your doctor or pharmacist. • suffer with porphyria (a genetic disorder • This medicine has been prescribed for of the red blood cells haemoglobin causing Other: hair loss, ringing in the ears, small you. Do not pass it on to others. It may skin blisters, abdominal pain and brain/ purple red spots. An increase risk of bone Pack sizes are 28 tablets harm them, even if their signs of illness nervous system disorders) fractures has been observed in patients are the same as yours. • are not able to pass water taking this type of medicine. Marketing Authorisation holder and • If you get any side effects, talk to your • have increased pressure in the eye Withdrawal symptoms: feeling or being sick, Manufacturer: Accord, Barnstaple, EX32 doctor or pharmacist. This includes any (glaucoma) stomach pain, diarrhoea, difficulty sleeping, 8NS, UK. possible side effects not listed in this • are taking monoamine oxidase inhibitors nervousness, anxiety, headache, irritability leaflet. See section 4. (MAOI) or you have taken MAOIs within the Children: changes in behaviour. This leaflet was last revised in previous 14 days for depression December 2020. • if the child is under 6 years old. Reporting of side effects What is in this leaflet If you get any side effects, talk to your doctor, 1 What Imipramine tablets are and Warnings and precautions pharmacist or nurse. This includes any what they are used for possible side effects not listed in this leaflet. You can also report side effects directly via 2 What you need to know before Thoughts of suicide and worsening of the Yellow Card Scheme at: www.mhra.gov. you take Imipramine tablets your depression or anxiety disorder If you are depressed and/or have anxiety uk/yellowcard or search for MHRA Yellow Card 3 How to take Imipramine tablets in the Google Play or Apple App Store. disorders you can sometimes have thoughts By reporting side effects you can help provide 4 Possible side effects of harming or killing yourself. These may be more information on the safety of this medicine. 5 How to store Imipramine tablets increased when first starting antidepressants, since these medicines all take time to work, 6 5 Contents of the pack and other usually about two weeks but sometimes How to store Imipramine tablets information longer. You may be more likely to think like this: Keep out of the sight and reach of children. • If you have previously had thoughts about What Imipramine tablets are and Store below 25°C in a dry place. 1 killing or harming yourself. Do not take Imipramine tablets after the what they are used for • If you are a young adult. Information from expiry date stated on the label/carton/bottle. clinical trials has shown an increased risk The expiry date refers to the last day of that Imipramine belongs to a group of medicines of suicidal behaviour in young adults month. called tricyclic antidepressant drugs. These (less than 25 years old) with psychiatric Do not throw away any medicines via medicines alter the levels of chemicals in the conditions who were treated with an wastewater or household waste. Ask your brain to relieve the symptoms of depression. antidepressant. pharmacist how to throw away medicines you Imipramine is used: If you have thoughts of harming or killing no longer use. These measures will help to • to treat the symptoms of depression. yourself at any time, contact your doctor or protect the environment. • for the relief of bed-wetting at night by go to a hospital straight away. children. You may find it helpful to tell a relative or close friend that you are depressed or have 6 Contents of the pack and other information 2 What you need to know before an anxiety disorder, and ask them to read this you take Imipramine Tablets leaflet. You might ask them to tell you if they think your depression or anxiety is getting What Imipramine tablets contain worse, or if they are worried about changes in • The active substance (the ingredient that Do not take Imipramine tablets and tell your your behaviour. makes the tablets work) is imipramine doctor if you or your child (if they are the hydrochloride. Each tablet contains either patient): 10mg or 25mg of the active ingredient. • are allergic (hypersensitive) to imipramine, other tricyclic antidepressants or any of the other ingredients (see section 6). Continued top of next column 50994808 BBBA9000 Continued top of next column Continued over page 296x210 Leaflet Reel Fed Bi Fold Profile (BST) page 4 page 1 Imipramine 10mg Tablets PIL -UK Imipramine, Tablets, 10 & 25 mg, 28s - UK approved for print/date Item number: BBBA9000 Colours Non Printing Colours JDE No.: 1. Black 1. Profile 50994808 Originator: R.Paul Dimensions: 296 x 210 Origination Date: Min Body Text Size: 2. 2. Dimensions: 296x210 (Reel Fed) 21.09.2020 8pt Revision Date: 07.12.2020 Supplier: Accord Barnstaple 3. 3. Component: Leaflet for Blisters Revised By: R.Paul 4. Pharmacode: 5. 4035 Proof Round Technical Date sent: N/A 6. Date Sent: 21-09-20 6 Approval Date received: Technologist: RH [email protected] Technically Approved Cartons and label leaflets only (labels only when specified) GTIN 13 (Belgium & Slovenia): German GTIN 14 (incorporating PZN): * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 6 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.12.2019 Check with your doctor or pharmacist • medicines to treat some heart conditions Dental check ups or you think a child may have swallowed before taking Imipramine tablets if you or such as diltiazem, verapamil, labetalol, As Imipramine tablets can cause problems any, contact your nearest hospital casualty your child (if they are the patient): propranolol, quinidine with your teeth, it is advisable to have regular department or tell your doctor immediately. • have any psychiatric disorder (eg • medicines to treat angina that you spray dental checks ups. Symptoms of an overdose include fast or schizophrenia or manic depression) or dissolve under your tongue (eg glyceryl irregular heartbeat, low blood pressure, • are taking buprenorphine. The use of trinitrate “GTN”, isosorbide dinitrate) Imipramine tablets contain drowsiness, fits, coma, agitation, muscle buprenorphine together with Imipramine • any medicines to treat high blood pressure • lactose and sucrose rigidity, being sick or fever. tablets can lead to serotonin syndrome, a such as guanethidine, debrisoquine, If you have been told by your doctor potentially life-threatening condition (see bethanidine methyldopa, reserpine, you have an intolerance to some sugars, If you forget to take Imipramine “Other medicines and Imipramine tablets”) clonidine or diuretics (“water” tablets) contact your doctor before taking this tablets • are withdrawing from alcohol or • medicines to treat some mental illnesses medicinal product. Do not take a double dose to make up for a medicines used to treat fits such as thioridazine, chlorpromazine • sunset yellow (E110), amaranth (E123), forgotten dose. If you forget to take a dose, • have ever had glaucoma or an enlarged • cimetidine (to treat ulcers) propylhydroxybenzoate (E216) and take another as soon as you remember and prostate gland • entacapone or selegiline (to treat methylhydroxybenzoate (E218) then your next dose at the usual time. • have an overactive thyroid gland and are Parkinson’s disease) Imipramine 10mg tablets contain sunset taking medicines to treat a thyroid disorder • oral contraceptives (“the pill”) or hormone yellow (E110) and amaranth (E123) which If you stop taking imipramine tablets • have a history of epilepsy or brain replacement therapy (HRT) may cause allergic reactions. Talk to your doctor before you stop taking damage • appetite suppressants Imipramine 25mg tablets contain the tablets and follow their advice as you • have low blood pressure or poor • sympathomimetic medicines propylhydroxybenzoate (E216) and may experience withdrawal symptoms (see circulation such as adrenaline (epinephrine), methylhydroxybenzoate (E218) which may section 4). • have severe kidney disease ephedrine, isoprenaline, noradrenaline cause allergic reactions (possibly delayed). (norepinephrine), phenylephrine and • have a tumour of the adrenal gland (eg • sodium benzoate (E211) 4 phaeochromocytoma or neuroblastoma) phenylpropanolamine (these may be This medicine contains sodium benzoate Possible side effects • suffer from panic attacks present in many cough and cold remedies 0.0025mg in each 10mg tablet and Like all medicines, Imipramine tablets can • suffer from long term constipation or local anaesthetics) 0.0022mg in each 25mg tablet.
Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000

    List of New Drugs Approved in India from 1991 to 2000

    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
  • Comparing the Effect of Venlafaxine and the Combination of Nortriptyline and Propranolol in the Prevention of Migraine

    Comparing the Effect of Venlafaxine and the Combination of Nortriptyline and Propranolol in the Prevention of Migraine

    Comparing the Effect of Venlafaxine and the Combination of Nortriptyline and Propranolol in the Prevention of Migraine Arash Mosarrezaii1, Mohammad Reza Amiri Nikpour1, Ata Jabarzadeh2 1Department of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran, 2Medical Student, Urmia University of Medical Sciences, Urmia, Iran Abstract Background: Migraine is a debilitating neurological condition, which can be categorized into episodic and chronic groups based on its clinical pattern. Avoiding the risk factors exacerbating migraine is not enough to reduce the frequency and severity of migraine headaches, and in the case of non-receiving proper drug treatment, episodic migraines have the potential to become chronic, which increases the risk of cardiovascular complications RESEARCH ARTICLE and leaves great impact on the quality of life of patients and increasing the health-care costs. The objective of this research was to compare the effects of venlafaxine (VFL) and nortriptyline and propranolol in preventing migraines. Methods: This research is an interventional study performed on 60 patients with migraine admitted to the neurological clinic. Patients were visited at 3 time intervals. In each stage, the variables of headache frequency, headache severity, nausea, vomiting, and drowsiness were recorded. Data were analyzed using SPSS 23 software. Results: VFL drug with a daily dose of 37.5 mg is not only more tolerable in the long term but also leaves better effect in reducing the frequency and severity of headaches compared to the combination of nortriptyline and propranolol. Conclusion: VFL is an appropriate, effective, and tolerable alternative to migraine treatment. Key words: Migraine, nortriptyline, propranolol, venlafaxine INTRODUCTION Patients with CM are less likely to have full-time job than patients with episodic type, and they are at risk of job igraine is known as a common incapacity, anxiety, chronic pain, and depression 2 times neurological disorder and causes more than patients with episodic migraine.
  • Research Article RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs

    Research Article RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs

    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
  • Schizophrenia Care Guide

    Schizophrenia Care Guide

    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid

    Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid

    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
  • TAYSIDE PRESCRIBER Issue No

    TAYSIDE PRESCRIBER Issue No

    TAYSIDE PRESCRIBER Issue No. 122 – May 2012 Produced by the NS Tayside Medicines Governance Unit in conjunction with Mental Health Citalopram & escitalopram:QT interval prolongation New maximum daily dose restrictions, contraindications, and warnings Information has been issued via Drug Safety Update, Volume 5, Issue 5, December 2011 and ‘Dear Healthcare Professional Letters’ for both citalopram and escitalopram regarding new restrictions on the maximum daily doses, contraindications, and warnings. This is as a result of an assessment of a QT study that revealed dose-dependent increase in the QT interval observed with ECG monitoring for both citalopram and escitalopram. Maximum licensed daily doses for citalopram and escitalopram Adults Adults > 65 years Adults with hepatic impairment Citalopram 40 mg 20 mg 20 mg Escitalopram (non-formulary) 20 mg 10 mg 10mg The guidance in NHS Tayside is: ⇒ to review all patients on high dose* citalopram or escitalopram with aim of reducing to new maximum licensed doses ( * above new maximum licensed daily doses as stated in the table above) ⇒ not to prescribe citalopram or escitalopram with other medication known to prolong the QT interval ⇒ not to prescribe citalopram and escitalopram in patients with known QT prolongation or congenital long QT syndrome ⇒ to consider alternative antidepressant in patients with cardiac disease ( e.g. patients with significant bradycardia; recent myocardial infarction or decompensated heart failure) See flow diagram on page 3 for further guidance and table below on medicines known to prolong the QT interval. Medicines known to increase plasma levels of citalopram or escitalopram, e.g. omeprazole & some antivirals may require dose reduction of citalopram or escitalopram and should be used with caution.
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016

    Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016

    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
  • NORPRAMIN® (Desipramine Hydrochloride Tablets USP)

    NORPRAMIN® (Desipramine Hydrochloride Tablets USP)

    NORPRAMIN® (desipramine hydrochloride tablets USP) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. NORPRAMIN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.) DESCRIPTION NORPRAMIN® (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type, and is chemically: 5H-Dibenz[bƒ]azepine-5-propanamine,10,11-dihydro-N-methyl-, monohydrochloride. 1 Reference ID: 3536021 Inactive Ingredients The following inactive ingredients are contained in all dosage strengths: acacia, calcium carbonate, corn starch, D&C Red No. 30 and D&C Yellow No. 10 (except 10 mg and 150 mg), FD&C Blue No. 1 (except 25 mg, 75 mg, and 100 mg), hydrogenated soy oil, iron oxide, light mineral oil, magnesium stearate, mannitol, polyethylene glycol 8000, pregelatinized corn starch, sodium benzoate (except 150 mg), sucrose, talc, titanium dioxide, and other ingredients.
  • PRODUCT MONOGRAPH ELAVIL® Amitriptyline Hydrochloride Tablets

    PRODUCT MONOGRAPH ELAVIL® Amitriptyline Hydrochloride Tablets

    PRODUCT MONOGRAPH ELAVIL® amitriptyline hydrochloride tablets USP 10, 25, 50 and 75 mg Antidepressant AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road Unit #1 August 29, 2018 Vaughan, ON L4K 4N7 Control No.: 217626 1 PRODUCT MONOGRAPH ELAVIL® amitriptyline hydrochloride tablets USP 10, 25, 50, 75 mg THERAPEUTIC CLASSIFICATION Antidepressant ACTIONS AND CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is a tricyclic antidepressant with sedative properties. Its mechanism of action in man is not known. Amitriptyline inhibits the membrane pump mechanism responsible for the re-uptake of transmitter amines, such as norepinephrine and serotonin, thereby increasing their concentration at the synaptic clefts of the brain. Amitriptyline has pronounced anticholinergic properties and produces EKG changes and quinidine-like effects on the heart (See ADVERSE REACTIONS). It also lowers the convulsive threshold and causes alterations in EEG and sleep patterns. Orally administered amitriptyline is readily absorbed and rapidly metabolized. Steady-state plasma concentrations vary widely and this variation may be genetically determined. Amitriptyline is primarily excreted in the urine, mostly in the form of metabolites, with some excretion also occurring in the feces. INDICATIONS AND CLINICAL USE ELAVIL® (amitriptyline hydrochloride) is indicated in the drug management of depressive illness. ELAVIL® may be used in depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression. Endogenous depression is more likely to be alleviated than are other depressive states. ELAVIL® ®, because of its sedative action, is also of value in alleviating the anxiety component of depression. As with other tricyclic antidepressants, ELAVIL® may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions.
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014

    Management of Major Depressive Disorder Clinical Practice Guidelines May 2014

    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

    A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.